Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome

• DOI: 10.20944/preprints202403.1322.v1
• Publication Date: 2024-03-25T07:58:31Z
• Authors: Yu Gao; Wu juan Li; Xiao Yu Huang; Yu hong Lyu; Chang wu Yue
• Keywords: 0303 health sciences; 03 medical and health sciences; probiotics; QH301-705.5; gut microbiome; dysbiosis; Review; Biology (General); prebiotics; metabolic syndrome

Previous investigations have illuminated the significant association between gut microbiome and a broad spectrum of health conditions, including obesity, diabetes, cardiovascular diseases, psychiatric disorders. Evidence from certain studies suggests that dysbiosis microbiota may play role in etiology obesity diabetes. Moreover, it is acknowledged dietary habits, pharmacological interventions, psychological stress, other exogenous factors can substantially influence microbial composition. For instance, diet rich fiber has been demonstrated to increase population beneficial bacteria, whereas consumption antibiotics reduce these advantageous communities. In light established correlation various pathologies, strategically altering profile represents an emerging therapeutic approach. This be accomplished through administration probiotics or prebiotics, which aim refine and, consequently, mitigate manifestations associated diseases. The present manuscript evaluates recent literature on relationship metabolic syndrome published over past three years anticipates future directions this evolving field.